LncRNA H19 Activates the RAS-MAPK Signaling Pathway via miR-140-5p/SOS1 Axis in Malignant Liver Tumors

This study confirms that H19 activates the Ras–#MAPK pathway via the miR 140 5p/#SOS1 axis, driving #LiverTumor proliferation and invasion, and provides a theoretical basis for the #clinical application of H19 in #Liver #CancerTherapy. #medsky

Read here: doi.org/10.1007/s115...

Brain Prize lecture at #ECNP2026 from Frank Winkler, Germany

🚨Don’t miss the Brain Prize Lecture by Frank Winkler, Germany, at the 39th ECNP Congress: 𝗠𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝘁 𝗻𝗲𝘁𝘄𝗼𝗿𝗸𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗯𝗿𝗮𝗶𝗻

📆 Monday 12 October at 10.15 CEST
📍In-person from Munich, Germany, and virtually

Read more : ow.ly/vsax50YBBYE

#Neuroscience #CancerTherapy #ClinicalNeuroscience #ECNP2026

New cancer therapies based on viral genes, for Diario Médico.
#art #illustration #digital #doctors #therapy #medicine #medicaljournal #virus #cancer #cancertherapy

An overview of how dysregulated epigenetic networks influence #CancerTherapy resistance and how targeting #Epigenetic regulators in combination with conventional therapies is a potential therapeutic strategy.

#STTT #OpenAccess: doi.org/10.1038/s413...

Corcept Gains FDA Approval for Cancer Therapy Corcept received FDA approval on Mar 25, 2026; shares rose ~28% intraday and market cap expanded by ~$600m, accelerating commercial and strategic options for the company.

Corcept Gains FDA Approval for Cancer Therapy: Corcept received FDA approval on Mar 25, 2026; shares rose ~28% intraday and market cap expanded by ~$600m, accelerating commercial and strategic options for… 👈 Read full analysis #Corcept #FDAApproval #CancerTherapy #PharmaNews #HealthcareInnovation

We're back with Day 2 of #MarkSymposium! Our first session, on novel cancer therapies, featured a powerhouse lineup including William Sellers, @amanglik.bsky.social, and @juliensage.bsky.social. The future of targeted treatment is bright. ⚡️ #CancerTherapy

Cancer cells can use oxygen starvation to outsmart death, shows new study | Research Matters Scientists have discovered that stressed cancer cells can pause their rapid growth and use a biological recycling trick to stay alive, challenging long-held beliefs about how aggressive cancers behave...

The innovative bio-sensor from BRIC-RGCB that tracks cancer’s survival secrets

For a deep dive, check out:
researchmatters.in/news/cancer-...

#cancer #cancertherapy #innovation #mitophagy #scicomm #science #sciencecommunication #IndianScience #ScienceinIndia

Engineered Probiotic E. coli Bacteria Produce Anticancer Drug Romidepsin and Target Tumors in Mouse Models Researchers from Shandong University in China have engineered the probiotic bacterium Escherichia coli Nissle 1917 (EcN) to function as a targeted drug delivery system for cancer treatment. By genetically modifying EcN, the team enabled it to biosynthesize romidepsin (also known as FK228), an FDA-approved histone deacetylase inhibitor with potent anticancer properties. In experiments, these modified bacteria accumulated preferentially inside solid tumors in mice, particularly in a breast cancer xenograft model using 4T1 cells, where they produced and released the drug directly at the tumor site. This approach leverages the natural tumor-colonizing ability of EcN, combined with localized drug production, to create a dual-action therapy: the bacteria induce an inflammatory response that supports anticancer activity, while romidepsin exerts its therapeutic effects with reduced systemic exposure. Results showed improved treatment efficacy compared to wild-type EcN, along with lower cardiotoxicity and mortality associated with romidepsin when delivered systemically. The strategy highlights the potential of synthetic biology in bacteria-mediated cancer therapy, offering more precise drug delivery that could minimize side effects common in traditional chemotherapy. However, the study emphasizes that this remains preclinical work in mice, with significant further research required to assess safety, bacterial clearance after treatment, potential immune responses, and translation to human trials. The findings establish a foundation for developing engineered bacteria as living factories for small-molecule anticancer agents in targeted therapies.

Engineered Probiotic E. coli Bacteria Produce Anticancer Drug Romidepsin and Target Tumors in Mouse Models

🤖 IA: It's clickbait ⚠️
👥 Usuarios: It's clickbait ⚠️

#cancertherapy #syntheticbiology #probioticbacteria

View full AI summary:

¿Pueden las farmacéuticas chinas desarrollar fármacos innovadores contra el cáncer? 🇨🇳💊

3 terapias de BeiGene:
💊 Zanubrutinib
💉 Tislelizumab
🧬 Pamiparib

🎥 Mira el video para conocer más.

#BeiGene #ChinesePharma #CancerTherapy #Oncology #DengYueMed

RESEARCH PAPER: Combinatorial use of VHL and KEAP1 PROTACs reveals unexpected synergy and hook effect relief
By Islam et al., and Luca Busino
➡️ https://genesdev.cshlp.org/content/40/5-6/308.abstract

Penn Medicine
#PROTAC #KRAS #cancer #cancertherapy

AI-guided A3F CBE evolution via ESM models
heA3F (W310D+S216T+H198D): 1.9× efficiency vs. A3A
haA3F-GA (+ N240G+Y359A): 3× precision, narrow editing window (pos 5-6)
In vivo PDAC: dual KRAS+MYC silencing → tumor suppression + survival benefit
www.nature.com/articles/s42...
#AIBiotech #CancerTherapy

This review describes the role of DEAD-box RNA helicases as critical hematopoiesis regulators, detailing how their post-transcriptional dysfunction promotes #HematologicalMalignancies and offers avenues for #CancerTherapy.

#OpenAccess: doi.org/10.1016/j.ge...

Post-transcriptional regulation of DEAD-box RNA helicases in hematopoietic malignancies

This review describes the role of DEAD-box RNA helicases as critical hematopoiesis regulators, detailing how their post-transcriptional dysfunction promotes #HematologicalMalignancies and offers avenues for #CancerTherapy.

#OpenAccess: doi.org/10.1016/j.ge...

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded Anktiva® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally - ImmunityBio

ImmunityBio reports ~700% year-over-year revenue growth for ANKTIVA®, backed by expanded approvals across lung and bladder cancer indications in 33 countries; a major commercial and treatment milestone. #CancerTherapy #ImmunityBio #CancerCare #TCSC
immunitybio.com/immunitybio-...

🆕 ADVANCE ONLINE 🆕

RESEARCH PAPER: Combinatorial use of VHL and KEAP1 PROTACs reveals unexpected synergy and hook effect relief
By Islam et al., and Luca Busino
➡️ genesdev.cshlp.org/content/early/2025/12/08...


#PROTAC #KRAS #cancer #cancertherapy

Magnetic micro/nano robots for physical cell stimulation: fundamentals, fabrication, and applications

This review explores advances in magnetic micro/nano robots for precise physical cell stimulation—detailing #actuation principles, #fabrication strategies, and #biomedical applications in #CancerTherapy, #RegenerativeMedicine and #antimicrobial treatment.
#IJEM: doi.org/10.1088/2631...

Dr. Olivier Micheau (INSERM) is currently on secondment at #CHIRONProject partner Anyo Labs (Gothenburg), where he presented his work, “TRAILs to Cancer Therapy.” The visit supported scientific exchange and collaboration.

#HorizonEurope #EUResearch #CancerResearch #CancerTherapy

Discover gene therapy fundamentals, vectors, and applications transforming modern medicine and biotechnology with BioResire’s quick learning guide.
#GeneTherapy #Biotechnology #GeneticEngineering #PrecisionMedicine #CancerTherapy #Genomics #MolecularMedicine #CRISPR #LifeSciences #BioResire

The Broermann Medical Innovation Award recognizes exactly this kind of science: bold, translational research that changes clinical practice and improves lives.

Nominate an outstanding scientist for the 2026 award by March 01.

#cancer #cancercure #cancertherapy

www.broermann-award.org/nomination/

RESEARCH PAPER: Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems
By Nelson et al., and Hilda Pickett
➡️ https://genesdev.cshlp.org/content/40/3-4/267.full

Children's Medical Research Institute
#cancertherapy #glioblastoma

Doctors use regorafenib tablets to treat advanced cancers because the drug delivers targeted treatment which provides patients with hope. Doctors often recommend regorafenib tablets 40 mg, as part of treatment plans for colorectal cancer, gastrointestinal stromal tumors, and liver cancer. The treatment value of regorafenib tablets 40 mg, derives from their capacity to inhibit various protein kinases which drive tumor development and vascularization. Patients need to follow dosage instructions with precision while they need to consult healthcare professionals about potential side effects before they begin regorafenib tablets 40 mg therapy.When researching options, many patients compare the regorafenib tablets 40 mg and review the regorafenib 40 mg tablet price to plan their treatment budget. Oddway international provides trustworthy information to assist patients who require authentic oncology medications and global supply chain assistance.

Regorafenib 40 mg Tablets Price, Side Effects & Generic - Oddway

www.oddwayinternational.com/regorafenib-...

#RegorafenibTablets40mg #RegorafenibTreatment #CancerTherapy #TargetedTherapy

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss the mechanisms of acquired resistance and the models to better study it. Finally, they promote integration of biomarker-driven strategies and cutting-edge technologies to advance predictive and proactive prevention in cancer therapy.

🥳 Our 3rd most downloaded #REVIEW in 2025:

Acquired resistance in cancer: towards targeted therapeutic strategies

#therapyresistance #cancertherapy @NatResCancer
#NRCtop10of2025

Take a deep dive into the rapidly evolving world of therapeutic #CancerVaccines with Dr. Elias Sayour and find out why he is so excited about upcoming developments.

Listen now 🔉 buff.ly/v17FleW

#OncSky #CancerTherapy

🩸Facts about Multiple Myeloma:

Clinical Efficacy and Survival Outcomes

#MultipleMyeloma #BispecificAntibodies #Immunotherapy #Teclistamab #Elranatamab #Daratumumab #ClinicalTrials #Oncology #HematologicMalignancies #CancerTherapy #HEMEHUB

Killing cancer cells with RNA therapeutics – BioNews Central A new study in mice hints at the potential to use tiny particles made with RNA molecules to deliver chemotherapy drugs and other therapies directly to tumors, killing cancer cells without generating an immune response or toxicity-related side effects

A new study in mice hints at the potential to use tiny #RNANanoparticles to deliver #ChemotherapyDrugs and other therapies directly to #tumors, killing #CancerCells without generating an immune response or toxicity-related #SideEffects. 
#RNATherapeutics #CancerTherapy

bims-p53act 2026-02-08 papers

New week, new report 🧬

My weekly Mutant p53 & anti-cancer therapy response report is out.

Fresh evidence on how TP53 mutations shape treatment response in cancer.

@biomednews.bsky.social

#p53 #Cancer #Oncology #CancerTherapy #BiomedsNews

biomed.news/bims-p53act/...

🩸🔬Today's question!

See the answer and explanation on the next slide.

#MultipleMyeloma #MAIATrial #FrontlineTherapy #Hematology #HemeOnc #ClinicalTrials #CancerTherapy #HEMEHUB #CyBorD #Daratumumab #Lenalidomide #Dexamethasone #DRd #Bortezomib #Thalidomide #Pomalidomide

🌍 You’re Invited to the 11th International Congress on Cancer Science and Radiology – 2026 🧬🩻
📅 Dates: July 22–23, 2026
📍 Venue: Hilton Tokyo Hotel
📌 Register now:
👉 cancertherapy.inovineconferences.com/registration...

#cancerscience #radiology #cancerresearch #cancertherapy #oncologyconference

RESEARCH PAPER: Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer
By Shao et al., and Maureen Murphy
➡️ https://genesdev.cshlp.org/content/40/3-4/199.full

The Wistar Institute
#ovariancancer #p53 #cancertherapy #endocrineresistance

🌍 Join Us as a Delegate — GSCST 2026 Welcomes You!
Be part of the 12th Global Summit on Cancer Science and Therapy
📅August 03–04, 2026
📍Zurich, Switzerland
🔗 Register here: cancer-events.com/registration...

#cancerscience #cancertherapy #oncologyconference #cáncer